Prosecution Insights
Last updated: April 19, 2026
Application No. 18/278,932

STERICALLY HINDERED N-ALIPHATIC N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME

Non-Final OA §103§112
Filed
Aug 25, 2023
Examiner
QIAN, YUN
Art Unit
1738
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Rutgers The State University Of New Jersey
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
3y 3m
To Grant
75%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
588 granted / 1081 resolved
-10.6% vs TC avg
Strong +20% interview lift
Without
With
+20.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
60 currently pending
Career history
1141
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
44.3%
+4.3% vs TC avg
§102
16.8%
-23.2% vs TC avg
§112
26.8%
-13.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1081 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Response to Election/Restrictions Applicant’s election without traverse of Group II claims 1-3 and 12 in the reply filed on 02/23/2026 is acknowledged. Claims 13-15, 17, 28-30, 33-34, 41-42, 51-52, 59-60 and 66 are withdrawn as non-elected Groups. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3 and 12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The limitation of “M is not BF4” recited in claim 1 line 8 from bottom is unclear and confused because the claimed formula (I) does not have M group. All other claims depend directly or indirectly from the rejected claims and are, therefore, also rejected under 35 USC § 112(b) for the reasons set forth above. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-3 and 12 are rejected under 35 U.S.C. 103 as being unpatentable over Archer et al. (WO 2010/118377 A2). Regarding claims 1 and 12, Archer et al. teach a ligand 13 having the structure as shown below (page 28): PNG media_image1.png 170 238 media_image1.png Greyscale As we see above, the ligand compound 13 taught by Archer et al. corresponds to the instant claimed compound formula (I), wherein X=BF4-, a=m=1, R1=R2=H, except R3, R4=CMe2CH2CMe3 with one additional methylene group (emphasis added). Although Archer et al. does not specifically disclose the claimed compounds such as per applicant claims 1 as per applicant and 1,3-bis(2,4,4-trimethylpentan-2-yl)-1H-imidazol-3-ium tetrafluoroborate as per applicant claim 12, the embodiment disclosed by Archer et al. have overall appearances that are basically the same as the instant claims. They are all have the core structure of a imidazolium groups and tetrafluoroborate counter anions. The only structure difference between the claimed compounds such as 1,3-bis(2,4,4-trimethylpentan-2-yl)-1H-imidazol-3-ium tetrafluoroborate of claim 12 and the ligand 13 of Archer et al. are that the prior art compound has one additional CH2 group inserted between the dimethylmethylene and tert-butyl group as the arrows indicated above. The prior art ligand compound 13 taught by Archer et al. is a true homologs of the claimed compounds including 1,3-bis(2,4,4-trimethylpentan-2-yl)-1H-imidazol-3-ium tetrafluoroborate, the similarity between the chemical structures is sufficiently close that one on ordinary skill in the arts would have been motivated to make the claimed compounds in searching for new ligand compounds. Therefore, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made See MPEP 2144.09 I-III. Regarding claims 2-3, as discussed above, the ligand compound 13 taught by Archer et al. has at least of R5 as being Me, X is BF- and m is 1. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to YUN QIAN whose telephone number is (571)270-5834. The examiner can normally be reached Monday-Thursday 10:00am-4:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sally A Merkling can be reached at 571-272-6297. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. YUN . QIAN Examiner Art Unit 1732 /YUN QIAN/Primary Examiner, Art Unit 1738
Read full office action

Prosecution Timeline

Aug 25, 2023
Application Filed
Mar 10, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600906
RED-LUMINESCENT PHOSPHOR WITH LONG AFTERGLOW AND FABRICATION METHOD THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12595171
Co-production of Hydrogen and Sulfuric Acid by Partial Oxidation of Sulfur
2y 5m to grant Granted Apr 07, 2026
Patent 12592423
PROCESS AND ITS PRODUCTS FOR SPENT LITHIUM-ION BATTERIES TREATMENT
2y 5m to grant Granted Mar 31, 2026
Patent 12589383
Spherical Titanium Silicalite Molecular Sieve Catalyst and Preparation Method Therefor
2y 5m to grant Granted Mar 31, 2026
Patent 12577126
METHOD FOR PRODUCING NICKEL PARTICLES, METHOD FOR PRODUCING NICKEL SULFATE, AND METHOD FOR PRODUCING POSITIVE ELECTRODE ACTIVE MATERIAL FOR SECONDARY BATTERIES
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
75%
With Interview (+20.3%)
3y 3m
Median Time to Grant
Low
PTA Risk
Based on 1081 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month